

Invest in UK Life Sciences

Inward investors see value and opportunity in the UK, a forward-thinking nation with a track record of scientific breakthroughs and a life sciences industrial strategy applying billions of pounds of new funding to deliver the next generation of life-changing treatments and technologies. There are five core benefits for life science investors in the UK:

1. A dynamic and global life science hub, connecting investors with customers, collaborators, supply chains, and innovation partners
2. An internationally competitive business and regulatory environment
3. A world-class biomedical science base, with access to unique talent, data and infrastructure
4. An expert clinical and research partner operating at scale in the NHS, which serves a diverse population
5. Long-standing partnerships between industry, government, academia, charities and the NHS

#1

#1 FOR FDI IN EUROPE

and a top 3 global life sciences hub



MORE THAN 80 NOBEL PRIZES

for discoveries underpinning biomedical and health innovation



2 OF THE TOP 3

universities in the world for life sciences



NEARLY 250,000 PEOPLE

working in industry, turnover of £74bn each year.



WORLD-FIRST PROGRAMMES

to integrate genomics, AI, and early diagnosis, and preventative population medicine in the NHS



ONE OF THE WORLD'S BEST COUNTRIES TO DO BUSINESS

ranked 1st globally by Forbes and 8th globally by World Bank, with the lowest Corporation Tax in the G7 at 19%



Case Study: UCB major investment

UCB, a global pharmaceutical company, is investing in one of two major global R&D hubs in the UK, with planned investment of £150-200 million in the facility and around £1 billion total investment over five years.

“At UCB, we are proud of our heritage in the UK. Our planned investment to support the construction of a major R&D hub in the UK will enable us to build upon our numerous active collaborations with UK universities, biotechs and medical research charities, and continue our successful track record of bringing innovative medicines discovered in the UK to patients globally.”

Jean-Christophe Tellier, Chief Executive Officer, UCB

Case Study: Google Health

NHS adopts app to identify acute kidney injury (AKI) in minutes, not days.

Detection of one of the biggest killers in the NHS has been cut from hours to minutes at the Royal Free Hospital in London thanks to the introduction of a new mobile app.

This has been developed by technology experts at Google Health in collaboration with clinicians at the Royal Free London NHS Foundation Trust (RFL) to help identify patients at risk of acute kidney injury (AKI). Thanks to the app, clinicians were able to respond to urgent AKI cases in 14 minutes or less - a process which, using existing systems, might otherwise have taken many hours.



Department for
International Trade

How we can help

On your investment journey will we connect you into a community of support. We are committed to helping you make the most of the opportunities to use the UK as your gateway to the world.

Contact us today:

lifescience@trade.gov.uk